|
KMID : 0351819980390010013
|
|
Kyunpook University Medical Journal
1998 Volume.39 No. 1 p.13 ~ p.22
|
|
|
Intervention Strategy for Hepatitis B virus Infection with HBsAg Immunization in Taegu, Korea(1990-1994) (IDRC sponsered)
|
|
Chung Tai-Ho
Kim Jung-Chul
Kim Moon-Kyu
Kim Haeng-Mi
Chung Hai-Lee
Lee Sang-Gil
|
|
|
Abstract
|
|
|
The coordinates pf Taegu, Korea, where this study was conducted, are 123 26~ logitude and 35 2´ latitude, with a population of 2,300,000 as of 1994. The ann~.~al mean temperature is 12.5, and the average temperature in January, the coldest month, is -1.6 C and that in August, the hottest, is 25.9 C. The annual average ofprecipitation is 962.8mm. The HBV carrier rate is reported to approximate 10%.
This study aimed at checking the efficacy to find out the feasibility of incorporation with the expend´.ed program of immunization with the Korean made vaccine, Hepaccine by Cheil food and chiemical Inc. by immunizing the babies born of HBV carrier mothers. The study was participated in by the departrnents of pediatrics of three ,general hospitals in Taegu in additio to pediatrics department and biomedical research laboratories of Kyungpook Nation University.
1. The women in confinement subjected to this study numbered 27,641 out of which 1,613 was HBsAg(+) HBeAg(+) accounted for 19.8% of HBsAg(+) monthers, 1.15% of the total subjc;cts.
2. Hepaccine(1.5ug and 3.0ug) vaccine was done at birth, one month, 2 month 3 times consecutively. Blood samples were collected after 2nd vaccination(2nd month after birth), at the4th and 16th month following birth.
3. Hepaccine 1.5ug vaccination: When blood was collected upon the 2nd vaccination, eith HBs,Ag(+) after 3rd vaccination 96.4% were positive. For the babies bom of HBsAg(+) HBeAg(-) mothers, 93.2% were HBsAb(+) after the 2nd vaccination, 97.4 were HBsAb(+) after 3rd vaccination(4months after birth). In the ease of Hepaccine, administration of 3.Oug and :I.SUg made no recognizable difference.
4. conclusively, plasma-derived HBsAg vaccine produced by Cheil food and chemical Inc. at differing EPI schedules is immunogenic and effective in the high and low risk babies.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|